CACNA1D and Parkinson disease: For example, selective inhibition of CaV3.2 could be of therapeutic benefit in certain types of pain (Marger et al., 2011), and selective inhibitors of CaV1.3 have potential for therapeutic use in Parkinson’s disease and other disorders (Striessnig et al., 2015).